# Phase 1 Hodgkin Disease trials recruiting: 20 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials in phase 1 for Hodgkin Disease that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Hodgkin Disease trials: 20 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/hodgkin-disease

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 20
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 24, 2026 | NCT07838649 | Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity | Washington University School of Medicine | Phase 1 | Not yet recruiting | Lymphoma Cancer, Breast Cancer, Cancer of the Breast, Non-Hodgkin Lymphoma, Hodgkin Lymphoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07838649) |
| July 27, 2026 | NCT07729397 | Autologous iC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma | The Methodist Hospital Research Institute | Phase 1 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), Anaplastic Large Cell... | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729397) |
| June 3, 2026 | NCT07623850 | A Phase I Study of JLM019 Injection | Jecho Biopharmaceuticals Co., Ltd. | Phase 1 | Recruiting | Advanced Solid Tumor (Phase 1), Hodgkin Lymphoma, Non-Hodgkin Lymphoma | 115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623850) |
| March 5, 2026 | NCT07451054 | CD45BE-HSPC + CART-45 Cells | University of Pennsylvania | Phase 1 | Recruiting | B-Cell Non-Hodgkin Lymphoma (NHL), Richter's Transformation, T-Cell Non-Hodgkin Lymphoma, Hodgkin Lymphoma | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07451054) |
| March 3, 2026 | NCT07444632 | Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid... | M.D. Anderson Cancer Center | Phase 1 | Recruiting | Lymphoid, Hodgkin Lymphoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07444632) |
| June 13, 2025 | NCT07020533 | A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing... | City of Hope Medical Center | Phase 1 | Recruiting | Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia... | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07020533) |
| January 1, 2025 | NCT06755450 | Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma | Aurigene Discovery Technologies Limited | Phase 1 | Recruiting | Relapsed Advanced Lymphomas | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06755450) |
| July 10, 2024 | NCT06494371 | A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma | Ruijin Hospital | Phase 1 | Recruiting | Hodgkin's Lymphoma, Anaplastic Large Cell Lymphoma | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06494371) |
| July 5, 2024 | NCT06487624 | An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors | FBD Biologics Limited | Phase 1 | Recruiting | Advanced Solid Tumor, Refractory Hodgkin Lymphoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06487624) |
| April 25, 2024 | NCT06383338 | A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma. | Murdoch Childrens Research Institute | Phase 1 | Recruiting | Hodgkin Lymphoma, Non Hodgkin Lymphoma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06383338) |
| December 20, 2023 | NCT06176690 | Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas | Baylor College of Medicine | Phase 1 | Recruiting | CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type, Anaplastic... | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06176690) |
| November 29, 2023 | NCT06150664 | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | Compass Therapeutics | Phase 1 | Recruiting | Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma... | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06150664) |
| April 5, 2023 | NCT05798897 | Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma | Marker Therapeutics, Inc. | Phase 1 | Recruiting | Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed, Non Hodgkin Lymphoma... | 79 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05798897) |
| September 19, 2022 | NCT05544968 | Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies | Medical College of Wisconsin | Phase 1 | Recruiting | Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma, CD30+ Anaplastic Large Cell Lymphoma, CD30+ Pleomorphic... | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05544968) |
| July 27, 2022 | NCT05476770 | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | Therapeutic Advances in Childhood Leukemia Consortium | Phase 1 | Recruiting | Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin... | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05476770) |
| March 9, 2022 | NCT05272384 | Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma | National Cancer Institute (NCI) | Phase 1 | Recruiting | Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Refractory... | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05272384) |
| December 11, 2020 | NCT04664179 | EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma | Baylor College of Medicine | Phase 1 | Recruiting | EBV-Related Hodgkin Lymphoma, EBV-Related Lymphoproliferative Disorder, EBV Related Non-Hodgkin's Lymphoma | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04664179) |
| September 28, 2016 | NCT02917083 | CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) | Baylor College of Medicine | Phase 1 | Recruiting | Hodgkin's Lymphoma, Non-Hodgkin Lymphoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02917083) |
| July 24, 2015 | NCT02508038 | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | University of Wisconsin, Madison | Phase 1 | Recruiting | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic Syndrome... | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02508038) |
| March 16, 2012 | NCT01555892 | Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE | Baylor College of Medicine | Phase 1 | Recruiting | Hodgkin's Disease, Non-Hodgkin's Lymphoma, Lymphoproliferative Disease, Lymphoma | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01555892) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Baylor College of Medicine | 4 |
| FBD Biologics Limited | 1 |
| Ruijin Hospital | 1 |
| Medical College of Wisconsin | 1 |
| Therapeutic Advances in Childhood Leukemia Consortium | 1 |
| Washington University School of Medicine | 1 |
| Aurigene Discovery Technologies Limited | 1 |
| Marker Therapeutics, Inc. | 1 |
| M.D. Anderson Cancer Center | 1 |
| The Methodist Hospital Research Institute | 1 |
| Murdoch Childrens Research Institute | 1 |
| University of Pennsylvania | 1 |
| University of Wisconsin, Madison | 1 |
| Compass Therapeutics | 1 |
| National Cancer Institute (NCI) | 1 |
| Jecho Biopharmaceuticals Co., Ltd. | 1 |
| City of Hope Medical Center | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 16 |
| China | 3 |
| Australia | 2 |
| Taiwan | 1 |
| India | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Legal services firms in the United States](https://specstream.ai/data/businesses/legal-services-firms/united-states)
- [Criminal defense law firms in the United States](https://specstream.ai/data/businesses/criminal-defense-law-firms/united-states)
- [Walk-in clinics in the United States](https://specstream.ai/data/businesses/walk-in-clinics/united-states)
- [Orthodontics practices in the United States](https://specstream.ai/data/businesses/orthodontics-practices/united-states)
- [Fabric wholesalers in the United States](https://specstream.ai/data/businesses/fabric-wholesalers/united-states)
- [Automotive companies in the United States](https://specstream.ai/data/businesses/automotive-companies/united-states)
